Results 31 to 40 of about 1,300 (156)

Effects of chemical myosin II cross‐bridge inhibitors on eccentric force production in skinned muscle fibres

Experimental Physiology, Volume 111, Issue 7, Page 3337-3356, 1 July 2026.
Abstract Eccentric muscle contractions are essential for locomotion and daily activities. Force during these contractions depends on both cross‐bridge (XB) and non‐cross‐bridge (non‐XB) elements, including titin, with contributions varying by fibre type and contraction velocity.
André Tomalka, Sven Weidner, Christian Rode, Tobias Siebert   +3 more
wiley   +1 more source

Metabolite‐sensitive cross‐bridge models of human atria reveal the impact of diabetes on muscle mechanoenergetics

The Journal of Physiology, Volume 604, Issue 13, Page 5316-5341, 1 July 2026.
Abstract figure legend In this study, we used mathematical modelling to explore the effect of diabetes on muscle mechanoenergetics. Our parameterisation of cross‐bridge models using data from non‐diabetic and diabetic human atrial tissues revealed lower values for cross‐bridge stiffness, detachment rates, attachment rates and lower ATP sensitivity in ...
Julia H. Musgrave, June‐Chiew Han, Marie‐Louise Ward, Andrew J. Taberner, Kenneth Tran   +4 more
wiley   +1 more source

Mavacamten facilitates myosin head ON‐to‐OFF transitions and shortens thin filament length in relaxed mouse skeletal muscle

Physiological Reports
The first‐in‐its‐class cardiac drug mavacamten shifts myosin heads towards a structurally inactive position where they lay along the helical tracks of the thick filament.
Michel N. Kuehn, Nichlas M. Engels, Devin L. Nissen, Johanna K. Freundt, Weikang Ma, Samantha P. Harris, Thomas C. Irving, Wolfgang A. Linke, Anthony L. Hessel   +8 more
doaj   +1 more source

Real-World Experience With Mavacamten in SRT-Eligible Obstructive HCM

JACC: Advances
Background: Mavacamten, a cardiac myosin inhibitor, has been shown to improve symptoms and reduce left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy (oHCM). However, real-world data regarding longer-term clinical outcomes,
Lusha W. Liang, MD, MS, Hiroo Takayama, MD, PhD, Tamim M. Nazif, MD, Linda Gojcaj, PA-C, Yuichi J. Shimada, MD, MPH, Shepard D. Weiner, MD   +5 more
doaj   +1 more source

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross‐sectional analysis

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1934-1939, June 2026.
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar, Chloe Ratcliffe, Videha Sharma, William G. Newman, Munir Pirmohamed, John McDermott   +5 more
wiley   +1 more source

Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Journal of Clinical Medicine, 2023
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by an increased left ventricular wall thickness in the absence of increased afterload conditions. In addition to diastolic dysfunction, obstruction of the left ventricular outflow tract is common in HCM and has an important influence on symptoms and outcome. Over the last five decades
Scholtz, Smita (PD Dr. med.), Rudolph, Volker (PD Dr. med.), Reil, Jan-Christian (Dr. med.)   +2 more
openaire   +3 more sources

MAVACAMTEN NO TRATAMENTO DA CARDIOMIOPATIA HIPERTRÓFICA

RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218, 2023
Introdução: A cardiomiopatia hipertrófica (CMH) é uma das doenças cardíacas genéticas mais comuns, afetando entre 0,16% e 0,29% da população adulta geral. É uma doença genética do miocárdio e caracteriza-se por acentuada hipertrofia miocárdica que não pode ser explicada pela carga pressórica ou pela presença de desarranjo miocitário.
Caique Pereira de Paiva, Ana Clara Godinho de Freitas, Carla Lana Germinari Souza, Felipe Tochihide Iamaguti, Genon Henrique Costa Pinto, Júlia Peruzzi Iamaguti, Marina Romaquela Rodrigues, Tagstan Ribeiro Moioli, Taís Barbosa Honorato, Carollayne Mendonça Rocha   +9 more
openaire   +1 more source

Electrophysiological Substrate and Ablation Outcomes in Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Propensity‐Matched Multicenter Study

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
Multicentre retrospective propensity‐score‐matched cohort study (n = 286; 3 centres, Pakistan; 2015‐2023) comparing electrophysiological substrate and 12‐month ablation outcomes in patients with atrial fibrillation and hypertrophic cardiomyopathy (HCM‐AF, red) versus lone atrial fibrillation (Lone AF, green; 1:1 PSM on 14 covariates).
Umair Abrar, Fazal Ghaffar, Muhammad Zuhaid, Huzaifa Bin Afzaal, Palwasha Abbasi, Muhammad Hasnain Iqbal, Moʻminov Jahongir Zokirjon oʻgʻli, Sifat Ullah Safi   +7 more
wiley   +1 more source

Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic‐Cardiodynamic Modeling to Support Safety and Efficacy

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT In the phase 3 study SEQUOIA‐HCM (NCT05186818), aficamten, a next‐in‐class cardiac myosin inhibitor, was safe and efficacious in participants with obstructive hypertrophic cardiomyopathy (oHCM). Using pharmacokinetics/pharmacodynamics (PKPD) modeling, we quantified the relationship between aficamten exposure and cardiodynamic measures of ...
Justin D. Lutz, Russ Wada, Daniel L. Jacoby, Stephen B. Heitner, Stuart Kupfer, Polina German   +5 more
wiley   +1 more source

Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration

CPT: Pharmacometrics & Systems Pharmacology
Mavacamten is a selective, allosteric, reversible cardiac myosin inhibitor that has been developed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Peter Chang, Vidya Perera, David H. Salinger, Samira Merali, Neelima Thanneer, Hyunmoon Back, Julie D. Seroogy, Daniel D. Gretler, Amy J. Sehnert, Maria Palmisano, Amit Roy   +10 more
doaj   +1 more source